Dr Agarwals Health Care Ltd

- Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24. - For the next 2-3 years, the company expects revenue growth from mature and new facilities combined to be around 20% annually. - Expansion is driven primarily by organic growth, with plans to open 8-10 new facilities per quarter and around 45-50 facilities per year. - Focus on core states: Tamil Nadu, Maharashtra, Karnataka, Andhra Pradesh, Telangana; with some expansion in northern regions like Gujarat, Jammu, Punjab. - Growth driven by increased footfall (6-7%), pricing increases (2-3%), and premiumization (6-7%). - Higher-end premium surgical procedures, such as cataract and refractive surgeries, with higher average ticket sizes (cataract ~INR 38,000; refractive ~INR 75,000-80,000), contribute significantly. - The overall eye-care market is projected to grow at 12-14% CAGR, with organized players currently serving 13-15% market share, indicating room for expansion.

- Mature facilities are growing at around 18% CAGR, which is expected to continue over the next 2-3 years. - Overall company revenue growth, combining mature and new facilities, is guided at approximately 20% CAGR for the next 2-3 years. - EBITDA margins are expected to sustain at current levels despite ongoing expansion and new facility openings. - The company plans to open around 45-50 new facilities annually, supporting growth. - PAT grew by 25% in Q3 FY25 with margin improvements; this positive trend is expected to continue. - Earnings per share (EPS) growth implied through PAT growth and margin stability; no explicit EPS forecast was given, but strong revenue and profitability growth suggest progressive EPS improvement. - Management emphasizes continued operational strength and strategic execution fueling sustained growth in earnings.

The transcript does not explicitly mention any current or expected orderbook or pending orders for Dr. Agarwal's Health Care Limited. However, relevant points on future operational expansion and growth plans include: - Target to open 8 to 10 new surgical facilities in Q4 FY 2025. - Added 42 new facilities in the current year, totaling 221 facilities as of December 31, 2024. - Plans to launch 7 primary facilities in Q4 FY 2025. - Focus on strengthening presence in core markets: Tamil Nadu, Maharashtra, Karnataka, Andhra Pradesh, Telangana. - Expanding into northern core states such as Gujarat, Jammu, and Odisha. - Approximately 75% to 80% of new center rollouts planned in 5 core clusters including Mumbai, Pune, Nashik, Satara, and Kerala. No direct details on orderbook or pending orders are provided. The emphasis is on organic growth and selective acquisitions if suitable.

- There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript. - Regarding acquisitions, it is noted that so far all acquisitions have been through cash payouts, with no equity dilution involved. - The management has expressed an intention to explore combinations or mergers between listed entities within the next three years, which might involve share swaps, but details and timelines are still under consideration. - No concrete plans or information about raising fresh debt or equity capital have been disclosed during the call.

- Focus remains predominantly on organic expansion, with plans to open 8-10 new facilities each quarter over the next few years. - Capex for primary (eye clinic) facilities ranges between INR 30-35 lakhs, with sizes between 750-1,500 sq ft. - Secondary facilities have a capex range of INR 4.5-7 crores, sized 4,000-7,000 sq ft (smaller in Mumbai). - No significant equity issuance has been done so far in acquisitions; acquisitions are primarily cash-based with deferred payments over 4 years. - Acquisitions are strategically targeted for entry into new markets (e.g., Delhi, UP, Punjab), with majority of growth in core markets via organic centers. - Example: Under-construction flagship tertiary hospital in Chennai, expected operational by early FY 2026. - Asset-light model with most facilities leased (220 out of 221), minimizing capital intensity. - No major expansion planned in Africa; focus is on stabilizing and moderate growth there.